

Ana Leo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2663564/publications.pdf>

Version: 2024-02-01

164
papers

9,441
citations

36271

51
h-index

42364

92
g-index

167
all docs

167
docs citations

167
times ranked

13818
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimitochondrial Antibodies: from Bench to Bedside. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 166-177.	2.9	29
2	Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19?. <i>Liver International</i> , 2022, 42, 274-276.	1.9	2
3	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
4	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
5	Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	0
6	Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury. <i>Digestive and Liver Disease</i> , 2022, 54, 722-726.	0.4	8
7	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels. <i>Liver International</i> , 2022, 42, 1692-1695.	1.9	4
8	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. <i>World Journal of Gastroenterology</i> , 2022, 28, 1430-1443.	1.4	5
9	Versatile Mass Spectrometry-Based Intraoperative Diagnosis of Liver Tumor in a Multiethnic Cohort. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4244.	1.3	3
10	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022, 10, 801.	2.1	13
11	Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. <i>Journal of Hepatology</i> , 2022, 77, 1359-1372.	1.8	30
12	A change of paradigm in PBC: Pursuing normal alkaline phosphatase. <i>EBioMedicine</i> , 2022, 82, 104150.	2.7	0
13	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	1.0	3
14	Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 906-908.	0.3	3
15	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	2.6	33
16	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. <i>Cancers</i> , 2021, 13, 2070.	1.7	6
17	Experimental liver models: From cell culture techniques to microfluidic organs-on-a-chip. <i>Liver International</i> , 2021, 41, 1744-1761.	1.9	28
18	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 839-843.	1.0	4

#	ARTICLE	IF	CITATIONS
19	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. <i>Liver International</i> , 2021, 41, 1909-1912.	1.9	1
20	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. <i>Hepatology</i> , 2021, 74, 2307-2307.	3.6	1
21	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021, 9, 787-796.	1.6	4
22	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
23	Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 933-936.	1.3	5
24	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
25	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9342.	1.3	2
26	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
27	Small and Large Bile Ducts Intrahepatic Cholangiocarcinoma Classification: A Preliminary Feature-Based Study. <i>Lecture Notes in Computer Science</i> , 2021, , 237-244.	1.0	0
28	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 034-048.	1.8	76
29	All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 51-53.	2.4	1
30	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. <i>Liver Cancer</i> , 2020, 9, 15-27.	4.2	56
31	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , 2020, 72, 359-360.	3.6	3
32	Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. <i>Liver International</i> , 2020, 40, 3117-3124.	1.9	27
33	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	1.7	28
34	Transcriptional Differences for COVID-19 Disease Map Genes between Males and Females Indicate a Different Basal Immunophenotype Relevant to the Disease. <i>Genes</i> , 2020, 11, 1447.	1.0	16
35	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. <i>Cancers</i> , 2020, 12, 2190.	1.7	38
36	Primary biliary cholangitis. <i>Lancet, The</i> , 2020, 396, 1915-1926.	6.3	126

#	ARTICLE	IF	CITATIONS
37	COVID-19 and liver cancer clinical trials: Not everything is lost. <i>Liver International</i> , 2020, 40, 1541-1544.	1.9	3
38	High mortality in COVID-19 patients with mild respiratory disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13314.	1.7	34
39	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
40	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
41	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020, 114, 102511.	3.0	72
42	Global characterization of tumor infiltrate of Intrahepatic Cholangiocarcinoma by single cell sequencing. <i>Digestive and Liver Disease</i> , 2020, 52, e48-e49.	0.4	0
43	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. <i>Journal of Leukocyte Biology</i> , 2020, 108, 715-721.	1.5	11
44	The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy of intrahepatic cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, e5.	0.4	0
45	Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications. <i>Digestive and Liver Disease</i> , 2020, 52, e55.	0.4	0
46	Impact of HBV infection in HCV/HBV coinfecting patients treated with DAAs IN Northern Italy. <i>Digestive and Liver Disease</i> , 2020, 52, e19-e20.	0.4	0
47	Directly acting antivirals are safe and effective in HCV elderly patients: a multicenter real life study. <i>Digestive and Liver Disease</i> , 2020, 52, e28.	0.4	0
48	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020, 40, 233-239.	1.8	4
49	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. <i>Updates in Surgery</i> , 2020, 72, 413-421.	0.9	9
50	Survival After Liver Transplantation for Autoimmune Hepatitis: Are We Messing With the Immune System?. <i>Liver Transplantation</i> , 2020, 26, 861-862.	1.3	1
51	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020, 73, 453-455.	1.8	51
52	Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis. <i>Updates in Surgery</i> , 2020, 72, 671-679.	0.9	5
53	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2366-2368.e3.	2.4	51
54	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	99

#	ARTICLE	IF	CITATIONS
55	Identifying medical professionals at risk for in-hospital COVID-19 infection: A snapshot during a "tsunami" highlighting unexpected risks. <i>Global Health & Medicine</i> , 2020, 2, 235-239.	0.6	1
56	Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. <i>World Journal of Gastroenterology</i> , 2020, 26, 4900-4918.	1.4	19
57	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
58	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019, 7, 875-880.	1.6	10
59	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	1.4	23
60	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019, 51, 1074-1078.	0.4	32
61	Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 148-150.	0.7	1
62	SAT-493-Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e850-e851.	1.8	0
63	Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. <i>Current Transplantation Reports</i> , 2019, 6, 134-145.	0.9	0
64	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2216-2224.	0.9	32
65	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
66	The tumour microenvironment and immune milieu of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 63-78.	1.9	109
67	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019, 100, 17-26.	3.0	33
68	Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2019, 156, 1930-1931.	0.6	0
69	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971.	1.7	57
70	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 5-6.	3.7	1
71	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.4	47
72	Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. <i>Digestive and Liver Disease</i> , 2019, 51, 549-550.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052.	1.4	92
74	Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Digestive and Liver Disease, 2018, 50, 46-47.	0.4	0
75	Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection. Digestive and Liver Disease, 2018, 50, 8.	0.4	0
76	Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. Digestive and Liver Disease, 2018, 50, 38-39.	0.4	0
77	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study. Digestive and Liver Disease, 2018, 50, 34-35.	0.4	0
78	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 1705-1712.	1.9	26
79	Common Variable Immunodeficiency and Liver Involvement. Clinical Reviews in Allergy and Immunology, 2018, 55, 340-351.	2.9	58
80	Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. Translational Gastroenterology and Hepatology, 2018, 3, 104-104.	1.5	0
81	Is Liver Injury an Affordable Risk of Immune Checkpoint Inhibitor Therapy for Cancer?. Gastroenterology, 2018, 155, 2021-2023.	0.6	6
82	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 570-574.	0.6	2
83	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepatic Oncology, 2018, 5, HEPO3.	4.2	14
84	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. Liver International, 2018, 38, 2342.	1.9	1
85	Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma—a composite scenario. Hepatobiliary Surgery and Nutrition, 2018, 7, 130-133.	0.7	11
86	Changes in the Epidemiology of Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 429-441.	1.0	20
87	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. Journal of Hepatology, 2018, 68, S86.	1.8	2
88	Filamin a expression predicts early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S382-S383.	1.8	0
89	The Epigenetics of Primary Biliary Cholangitis. , 2018, , 251-272.		0
90	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology, 2018, 8, 181.	1.3	19

#	ARTICLE	IF	CITATIONS
91	Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection. <i>Journal of Hepatology</i> , 2018, 68, S425-S426.	1.8	0
92	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
93	Human β -Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e80.	1.3	3
94	Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good?. <i>Liver International</i> , 2017, 37, 1110-1112.	1.9	1
95	Primary biliary cholangitis: a comprehensive overview. <i>Hepatology International</i> , 2017, 11, 485-499.	1.9	82
96	Geoeidemiology and the Impact of Sex on Autoimmune Diseases. , 2017, , 323-333.		0
97	The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 650-659.	0.7	26
98	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016, 185, 61-71.	1.1	75
99	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016, 6, 25906.	1.6	132
100	A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. <i>Digestive and Liver Disease</i> , 2016, 48, e233.	0.4	0
101	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
102	Making Sense of Autoantibodies in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016, 20, 33-46.	1.0	22
103	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0159612.	1.1	23
104	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	1.4	22
105	Geoeidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , 2015, 33, 94-101.	0.8	32
106	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 633-643.	0.9	31
107	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015, 220, 1025-1029.	0.8	20
108	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015, 47, 432-435.	0.4	26

#	ARTICLE	IF	CITATIONS
109	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015, 6, 8019.	5.8	245
110	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
111	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015, 7, 61.	1.8	83
112	Genetics and Epigenetics of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 255-264.	1.8	42
113	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
114	Role of Cholangiocytes in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 273-284.	1.8	37
115	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. <i>Frontiers in Immunology</i> , 2014, 5, 128.	2.2	57
116	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 363-368.	0.4	11
117	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , 2014, 44, 945-954.	1.6	34
118	What Is an Autoantibody?. , 2014, , 13-20.		1
119	Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , 2014, 60, 1314-1323.	3.6	68
120	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. <i>Hepatology</i> , 2013, 57, 1498-1508.	3.6	58
121	Apoptosis and innate immune system: Novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013, 45, 630-636.	0.4	24
122	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 46, 81-87.	3.0	64
123	Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 41, 87-91.	3.0	93
124	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S388.	1.8	0
125	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013, 14, 179-186.	2.2	52
126	ImmunoChIP analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	1.4	139

#	ARTICLE	IF	CITATIONS
127	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	2.2	75
128	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012, 3, 127-132.	3.9	4
129	Towards common denominators in primary biliary cirrhosis: The role of IL-12. <i>Journal of Hepatology</i> , 2012, 56, 731-733.	1.8	38
130	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , 2012, 38, J193-J196.	3.0	64
131	The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , 2012, 38, J187-J192.	3.0	277
132	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , 2012, 12, 92.	0.8	24
133	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 1495-1506.	3.6	35
134	Geoeidemiology, gender and autoimmune disease. <i>Autoimmunity Reviews</i> , 2012, 11, A386-A392.	2.5	144
135	Autoimmunity and Turner's syndrome. <i>Autoimmunity Reviews</i> , 2012, 11, A538-A543.	2.5	73
136	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. <i>Clinical and Experimental Immunology</i> , 2012, 169, 253-262.	1.1	52
137	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 153-160.	3.6	116
138	Melatonin Inhibits In Vivo Cholangiocarcinoma Growth by Enhanced Biliary Expression of Serotonin N-Acetyltransferase (AANAT) the Key Enzyme Involved in Melatonin Synthesis. <i>Gastroenterology</i> , 2011, 140, S-910.	0.6	0
139	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. <i>Clinical and Experimental Immunology</i> , 2011, 165, 243-250.	1.1	34
140	Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. <i>Journal of Gastroenterology</i> , 2011, 46, 29-38.	2.3	32
141	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. <i>Immunity and Ageing</i> , 2011, 8, 12.	1.8	25
142	B cell depletion therapy exacerbates murine primary biliary cirrhosis. <i>Hepatology</i> , 2011, 53, 527-535.	3.6	66
143	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , 2011, 54, 196-203.	3.6	60
144	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011, 6, 95-102.	1.3	74

#	ARTICLE	IF	CITATIONS
145	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth. American Journal of Physiology - Renal Physiology, 2011, 301, G623-G633.	1.6	46
146	Definition of human autoimmunity " autoantibodies versus autoimmune disease. Autoimmunity Reviews, 2010, 9, A259-A266.	2.5	210
147	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology, 2010, 52, 987-998.	3.6	194
148	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
149	Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal of Hepatology, 2010, 52, 712-717.	1.8	50
150	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 176-180.	3.0	64
151	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 436-442.	3.0	123
152	Innate Immunity and Primary Biliary Cirrhosis. Current Molecular Medicine, 2009, 9, 45-51.	0.6	63
153	The immunological potential of galectin-1 and -3. Autoimmunity Reviews, 2009, 8, 360-363.	2.5	96
154	Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology, 2009, 49, 871-879.	3.6	193
155	Primary biliary cirrhosis is associated with altered hepatic microRNA expression. Journal of Autoimmunity, 2009, 32, 246-253.	3.0	191
156	Treatment with PEG-interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis. Annals of the New York Academy of Sciences, 2009, 1173, 847-857.	1.8	11
157	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48, 1906-1912.	3.6	120
158	Is autoimmunity a matter of sex?. Autoimmunity Reviews, 2008, 7, 626-630.	2.5	172
159	The consequences of apoptosis in autoimmunity. Journal of Autoimmunity, 2008, 31, 257-262.	3.0	122
160	Etiopathogenesis of primary biliary cirrhosis. World Journal of Gastroenterology, 2008, 14, 3328.	1.4	80
161	Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases. Seminars in Liver Disease, 2007, 27, 161-172.	1.8	100
162	Autophagy: Highlighting a novel player in the autoimmunity scenario. Journal of Autoimmunity, 2007, 29, 61-68.	3.0	91

#	ARTICLE	IF	CITATIONS
163	Primary Biliary Cirrhosis and Autoimmune Cholangitis. , 2007, , 235-247.		1
164	Hla class II antigens assoiated with lupus nephritis in italian SLE patients. Human Immunology, 2003, 64, 462-468.	1.2	54